Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months

TLDR FDA approved BYSANTI (milsaperidone) for Bipolar I manic episodes and Schizophrenia in adults VNDA stock jumped up to 44% after-hours on the news Patent protection runs to 2044, blocking generic competition for nearly two decades Second FDA approval for Vanda in under two months, following NEREUS in December 2025 BYSANTI launch expected by Q3 [...]

The post Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months appeared first on Blockonomi.